Expression of NEDD9 in hepatocellular carcinoma and its clinical significance

Lu,Peng; Wang,Zhi-Peng; Dang,Zheng; Zheng,Zhi-Gang; Li,Xiao; Zhou,Liang; Ding,Rui; Yue,Shu-Qiang; Dou,Ke-Feng

doi:10.3892/or.2015.3863

Expression of NEDD9 in hepatocellular carcinoma and its clinical significance

Authors:
- Peng Lu
- Zhi-Peng Wang
- Zheng Dang
- Zhi-Gang Zheng
- Xiao Li
- Liang Zhou
- Rui Ding
- Shu-Qiang Yue
- Ke-Feng Dou
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreaticosplenic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, Shanxi, P.R. China, Department of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shanxi, P.R. China, Department of Hepatobiliary Surgery, Lanzhou General Hospital of PLA, Lanzhou, Gansu, P.R. China, Department of General Surgery, The 155 Central Hospital of PLA, Kaifeng, He'nan, P.R. China
Published online on: March 18, 2015 https://doi.org/10.3892/or.2015.3863
Pages: 2375-2383

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neural precursor cell expressed, developmentally downregulated 9 (NEDD9) plays an integral role in natural and pathological cell biology. Overexpression of NEDD9 protein has been correlated with poor prognosis in various types of cancer. However, few available data address the precise function of the NEDD9 gene in hepatocellular carcinoma (HCC). In the present study, we investigated NEDD9 expression in 40 primary human HCC tissues compared with matched adjacent non-tumor hepatic tissues using RT-qPCR and western blot analysis. Immunohistochemistry was performed to analyze the correlations between NEDD9 expression and clinicopathological factors. Statistical analyses were applied to derive prognostic values of NEDD9 in HCC. The results showed that the NEDD9 mRNA and protein expression levels in HCC tissues were significantly higher than those in matched adjacent non-tumor hepatic tissues. High NEDD9 expression was correlated with larger tumor size, advanced tumor grade, metastasis, intrahepatic venous invasion and high UICC TNM stages in HCC patients. Patients with high NEDD9 expression levels exhibited poorer recurrence-free and overall survival than those with a low NEDD9 expression. Additionally, NEDD9 expression status was an independent prognostic factor for survival. This correlation remained significant in patients with early-stage HCC or with normal serum AFP levels. The results of this study suggest that NEDD9 may be a valuable prognostic biomarker for HCC, including early-stage and AFP-normal patients.

View Figures

View References

1	Nordenstedt H, White DL and El-Serag HB: The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 42(Suppl 3): S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
3	Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in the Asia-Pacifc region: consensus statements. J Gastroenterol Hepatol. 25:657–663. 2010. View Article : Google Scholar
4	Yuen MF, Hou JL and Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 24:346–353. 2009. View Article : Google Scholar : PubMed/NCBI
5	Schwartz ME and Shrager B: Surgical resection for hepatocellular carcinoma in the noncirrhotic: the Western experience. Recent Results Cancer Res. 190:85–100. 2013. View Article : Google Scholar
6	Yang Y, Nagano H, Ota H, et al: Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 141:196–202. 2007. View Article : Google Scholar : PubMed/NCBI
7	Tang ZY, Ye SL, Liu YK, et al: A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 130:187–196. 2004. View Article : Google Scholar
8	Yang LY, Tao YM, Ou DP, Wang W, Chang ZG and Wu F: Increased expression of Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 correlated with poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 12:5673–5679. 2006. View Article : Google Scholar : PubMed/NCBI
9	Okuda K: Hepatocellular carcinoma: clinicopathological aspects. J Gastroenterol Hepatol. 12:S314–S318. 1997. View Article : Google Scholar
10	Tandon P and Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI
11	Di Bisceglie AM: Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology. 127(Suppl 1): S104–S107. 2004. View Article : Google Scholar : PubMed/NCBI
12	Daniele B, Bencivenga A, Megna AS and Tinessa V: α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 127(Suppl 1): S108–S112. 2004. View Article : Google Scholar : PubMed/NCBI
13	Farinati F, Marino D, De Giorgio M, et al: Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 101:524–532. 2006. View Article : Google Scholar : PubMed/NCBI
14	Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y and Morimoto C: Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in β1 integrin-mediated signaling in lymphocytes. J Exp Med. 184:1365–1375. 1996. View Article : Google Scholar : PubMed/NCBI
15	Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G and Golemis EA: Human enhancer of filamentation 1, a novel p130^cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol. 16:3327–3337. 1996.PubMed/NCBI
16	Kumar S, Tomooka Y and Noda M: Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 185:1155–1161. 1992. View Article : Google Scholar : PubMed/NCBI
17	Tikhmyanova N, Little JL and Golemis EA: CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 67:1025–1048. 2010. View Article : Google Scholar :
18	Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature. 436:518–524. 2005. View Article : Google Scholar : PubMed/NCBI
19	Natarajan M, Stewart JE, Golemis EA, et al: HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 25:1721–1732. 2006. View Article : Google Scholar
20	Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 125:1269–1281. 2006. View Article : Google Scholar : PubMed/NCBI
21	Xue YZ, Sheng YY, Liu ZL, et al: Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumour Biol. 34:895–899. 2013. View Article : Google Scholar
22	Guerrero MS, Parsons JT and Bouton AH: Cas and NEDD9 contribute to tumor progression through dynamic regulation of the cytoskeleton. Genes Cancer. 3:371–381. 2012. View Article : Google Scholar : PubMed/NCBI
23	Astier A, Manié SN, Law SF, et al: Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma. 28:65–72. 1997.
24	Lucas JT Jr, Salimath BP, Slomiany MG and Rosenzweig SA: Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene. 29:4449–4459. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kong C, Wang C, Wang L, et al: NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One. 6:e226662011. View Article : Google Scholar : PubMed/NCBI
26	Tikhmyanova N and Golemis EA: NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One. 6:e221022011. View Article : Google Scholar : PubMed/NCBI
27	Thao le B, Vu HA, Yasuda K, et al: Cas-L was over-expressed in imatinib-resistant gastrointestinal stromal tumor cells. Cancer Biol Ther. 8:683–688. 2009. View Article : Google Scholar : PubMed/NCBI
28	Nagasue N: Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg. 5:7–13. 1998. View Article : Google Scholar : PubMed/NCBI
29	Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC and Hsu HC: High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutations. Int J Cancer. 112:44–50. 2004. View Article : Google Scholar : PubMed/NCBI
30	Trevisani F, D’Intino PE, Morselli-Labate AM, et al: Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 34:570–575. 2001. View Article : Google Scholar : PubMed/NCBI